Cargando…
Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
Tumor necrosis factor-α inhibitors are monoclonal antibodies that are commonly used in the treatment of inflammatory bowel disease. A rare side effect of these biological agents is chronic inflammatory demyelinating polyneuropathy, which is a debilitating disease characterized by weakness, sensory d...
Autores principales: | Larson, Jessica, Twohig, Patrick, Hutchins, Kathryn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946395/ https://www.ncbi.nlm.nih.gov/pubmed/36846359 http://dx.doi.org/10.14309/crj.0000000000000993 |
Ejemplares similares
-
Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease
por: Kamel, Amir Y., et al.
Publicado: (2016) -
Chronic Inflammatory Demyelinating Polyneuropathy in Patients With Crohn’s Disease on Infliximab Therapy
por: Almuntashri, Fahad, et al.
Publicado: (2021) -
Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018) -
Fibrillary glomerulonephritis combined with chronic inflammatory demyelinating polyneuropathy
por: Sung, Woo Kyung, et al.
Publicado: (2015) -
Inflammatory demyelinating polyneuropathy after total hip arthroplasty
por: Hess, Shane R., et al.
Publicado: (2018)